Notably, various clinical trials have demonstrated that Tirzepatide, a dual GLP‐1 and GIP receptor agonist, is not associated with an increased risk of pancreatitis in individuals with type 2 diabetes and obesity. Here, GLP1R is linked to type 2 diabetes mellitus.